John Gabriel Connolly, S.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pharmacoepidemiology | 2 | 2020 | 323 | 1.100 |
Why?
|
| Lawyers | 1 | 2019 | 38 | 0.660 |
Why?
|
| Vasculitis | 1 | 2022 | 519 | 0.630 |
Why?
|
| Angioedema | 1 | 2019 | 187 | 0.620 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2020 | 214 | 0.620 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2019 | 469 | 0.520 |
Why?
|
| Parkinson Disease, Secondary | 1 | 2015 | 126 | 0.520 |
Why?
|
| Propensity Score | 3 | 2020 | 1781 | 0.450 |
Why?
|
| Thiazolidinediones | 1 | 2015 | 476 | 0.420 |
Why?
|
| Databases, Factual | 5 | 2020 | 7729 | 0.410 |
Why?
|
| Epidemiologic Methods | 1 | 2016 | 1364 | 0.380 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 1584 | 0.380 |
Why?
|
| PrPC Proteins | 3 | 2009 | 37 | 0.380 |
Why?
|
| Hypoglycemic Agents | 3 | 2015 | 2872 | 0.320 |
Why?
|
| Anticoagulants | 2 | 2022 | 4599 | 0.310 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 3255 | 0.290 |
Why?
|
| Insurance Claim Review | 2 | 2020 | 720 | 0.250 |
Why?
|
| Medicare | 2 | 2020 | 6566 | 0.240 |
Why?
|
| Cohort Studies | 8 | 2022 | 40561 | 0.240 |
Why?
|
| Atrial Fibrillation | 1 | 2022 | 5034 | 0.230 |
Why?
|
| Hospitalization | 3 | 2022 | 10262 | 0.210 |
Why?
|
| Antipsychotic Agents | 1 | 2015 | 3057 | 0.200 |
Why?
|
| Stroke | 1 | 2022 | 9981 | 0.180 |
Why?
|
| Algorithms | 1 | 2020 | 13881 | 0.170 |
Why?
|
| Data Interpretation, Statistical | 2 | 2020 | 2716 | 0.170 |
Why?
|
| PrPSc Proteins | 2 | 2009 | 32 | 0.170 |
Why?
|
| Fluoroquinolones | 1 | 2020 | 310 | 0.160 |
Why?
|
| Xenopus laevis | 1 | 2002 | 957 | 0.160 |
Why?
|
| Isotretinoin | 1 | 2019 | 114 | 0.160 |
Why?
|
| Pyridones | 1 | 2022 | 712 | 0.150 |
Why?
|
| Oocytes | 1 | 2002 | 1187 | 0.150 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 5751 | 0.140 |
Why?
|
| Aortic Aneurysm | 1 | 2020 | 643 | 0.130 |
Why?
|
| Odds Ratio | 2 | 2020 | 9849 | 0.130 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2019 | 430 | 0.130 |
Why?
|
| Dermatologic Agents | 1 | 2019 | 278 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2015 | 6600 | 0.130 |
Why?
|
| Alendronate | 1 | 2016 | 171 | 0.130 |
Why?
|
| Hyperkinesis | 1 | 2015 | 89 | 0.130 |
Why?
|
| Insulin, Long-Acting | 1 | 2014 | 57 | 0.120 |
Why?
|
| Computer Simulation | 2 | 2020 | 6196 | 0.120 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 2029 | 0.120 |
Why?
|
| Drugs, Generic | 1 | 2019 | 421 | 0.120 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2016 | 320 | 0.120 |
Why?
|
| Affective Disorders, Psychotic | 1 | 2015 | 191 | 0.120 |
Why?
|
| Warfarin | 1 | 2022 | 1496 | 0.120 |
Why?
|
| Simvastatin | 1 | 2016 | 360 | 0.110 |
Why?
|
| Venous Thrombosis | 1 | 2022 | 1239 | 0.110 |
Why?
|
| Conduct Disorder | 1 | 2015 | 241 | 0.110 |
Why?
|
| Drug Utilization | 1 | 2019 | 1183 | 0.110 |
Why?
|
| Risperidone | 1 | 2015 | 383 | 0.110 |
Why?
|
| Drug Labeling | 1 | 2014 | 233 | 0.110 |
Why?
|
| Influenza, Human | 1 | 2022 | 1479 | 0.100 |
Why?
|
| Osteoporotic Fractures | 1 | 2016 | 401 | 0.100 |
Why?
|
| Blood Glucose | 3 | 2015 | 6256 | 0.100 |
Why?
|
| Monte Carlo Method | 1 | 2016 | 1254 | 0.090 |
Why?
|
| United States | 6 | 2022 | 69872 | 0.090 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 2376 | 0.090 |
Why?
|
| Data Collection | 1 | 2019 | 3341 | 0.090 |
Why?
|
| Benzodiazepines | 1 | 2015 | 1101 | 0.080 |
Why?
|
| Internationality | 1 | 2014 | 1003 | 0.080 |
Why?
|
| Bone Density Conservation Agents | 1 | 2016 | 773 | 0.080 |
Why?
|
| Humans | 19 | 2022 | 744343 | 0.080 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2016 | 1130 | 0.080 |
Why?
|
| Insulin | 2 | 2013 | 6580 | 0.080 |
Why?
|
| Thiazoles | 1 | 2015 | 1483 | 0.080 |
Why?
|
| Guideline Adherence | 2 | 2015 | 2266 | 0.070 |
Why?
|
| Prion Diseases | 1 | 2008 | 88 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2002 | 13033 | 0.070 |
Why?
|
| Insurance, Health | 1 | 2019 | 2494 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 2282 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2015 | 11725 | 0.070 |
Why?
|
| Aged | 6 | 2022 | 163280 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 14722 | 0.060 |
Why?
|
| Brain Chemistry | 1 | 2008 | 981 | 0.060 |
Why?
|
| Piperazines | 1 | 2015 | 2488 | 0.060 |
Why?
|
| Molecular Weight | 2 | 2005 | 2255 | 0.060 |
Why?
|
| Prions | 1 | 2005 | 180 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2016 | 3589 | 0.060 |
Why?
|
| Anxiety Disorders | 1 | 2015 | 2690 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2022 | 77449 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 7181 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2015 | 3748 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2019 | 21746 | 0.050 |
Why?
|
| Platelet Activation | 1 | 2005 | 673 | 0.050 |
Why?
|
| Parkinson Disease | 1 | 2015 | 2775 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 2009 | 9274 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2022 | 23338 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2012 | 2063 | 0.050 |
Why?
|
| Myocardial Infarction | 1 | 2022 | 11727 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 12354 | 0.050 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2013 | 3068 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2015 | 7279 | 0.050 |
Why?
|
| Psychotic Disorders | 1 | 2015 | 3046 | 0.040 |
Why?
|
| Mass Screening | 1 | 2015 | 5255 | 0.040 |
Why?
|
| Glycosylation | 1 | 2002 | 1126 | 0.040 |
Why?
|
| Female | 8 | 2022 | 380194 | 0.040 |
Why?
|
| Cardiovascular Diseases | 2 | 2016 | 15165 | 0.040 |
Why?
|
| Endopeptidases | 1 | 2002 | 772 | 0.040 |
Why?
|
| Male | 7 | 2022 | 350118 | 0.040 |
Why?
|
| Cricetinae | 1 | 2002 | 2472 | 0.040 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 2 | 2009 | 89 | 0.040 |
Why?
|
| Sertraline | 1 | 2019 | 206 | 0.040 |
Why?
|
| Smoking | 1 | 2013 | 8987 | 0.040 |
Why?
|
| Protein Transport | 1 | 2002 | 1988 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2013 | 10943 | 0.030 |
Why?
|
| Risk Factors | 2 | 2020 | 72290 | 0.030 |
Why?
|
| Immunoprecipitation | 2 | 2009 | 905 | 0.030 |
Why?
|
| Citalopram | 1 | 2019 | 403 | 0.030 |
Why?
|
| Thromboembolism | 1 | 2022 | 986 | 0.030 |
Why?
|
| Temperature | 1 | 2002 | 2206 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2022 | 57776 | 0.030 |
Why?
|
| Models, Animal | 1 | 2002 | 2171 | 0.030 |
Why?
|
| Prognosis | 1 | 2016 | 29063 | 0.030 |
Why?
|
| Blood Platelets | 1 | 2005 | 2508 | 0.030 |
Why?
|
| Urinary Tract Infections | 1 | 2020 | 788 | 0.030 |
Why?
|
| Incidence | 2 | 2022 | 20947 | 0.030 |
Why?
|
| Legislation, Drug | 1 | 2014 | 206 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2015 | 41006 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 3870 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 3768 | 0.020 |
Why?
|
| Risk | 1 | 2022 | 9687 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2008 | 5179 | 0.020 |
Why?
|
| Pneumonia | 1 | 2020 | 2133 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2013 | 1460 | 0.020 |
Why?
|
| Gerstmann-Straussler-Scheinker Disease | 1 | 2008 | 10 | 0.020 |
Why?
|
| Thrombosis | 1 | 2022 | 2968 | 0.020 |
Why?
|
| Epitope Mapping | 1 | 2009 | 311 | 0.020 |
Why?
|
| Hybridomas | 1 | 2009 | 452 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2013 | 2971 | 0.020 |
Why?
|
| Child | 1 | 2015 | 77709 | 0.020 |
Why?
|
| Adolescent | 1 | 2015 | 85781 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2009 | 1095 | 0.020 |
Why?
|
| Octoxynol | 1 | 2005 | 77 | 0.020 |
Why?
|
| Ionophores | 1 | 2005 | 108 | 0.020 |
Why?
|
| Logistic Models | 1 | 2020 | 13408 | 0.020 |
Why?
|
| Chromatography, Ion Exchange | 1 | 2005 | 305 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 2005 | 549 | 0.020 |
Why?
|
| Protein Structure, Quaternary | 1 | 2005 | 436 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2002 | 12072 | 0.010 |
Why?
|
| Mice | 3 | 2009 | 81183 | 0.010 |
Why?
|
| Mice, Knockout | 2 | 2009 | 14557 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2005 | 1801 | 0.010 |
Why?
|
| Copper | 1 | 2005 | 366 | 0.010 |
Why?
|
| Middle Aged | 3 | 2022 | 213383 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 2278 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2019 | 63114 | 0.010 |
Why?
|
| Animals | 3 | 2009 | 168757 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2013 | 4558 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 9959 | 0.010 |
Why?
|
| Disease Progression | 1 | 2012 | 13284 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 11366 | 0.010 |
Why?
|
| Cell Line | 1 | 2008 | 15997 | 0.010 |
Why?
|
| Calcium | 1 | 2005 | 5756 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 25043 | 0.010 |
Why?
|